Skip to main content

Agora
Sign in

House bill · H.R. 1843 (119th Congress)

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

U.S. House of Representatives

Latest action Mar 5, 2025

Sponsor: Neal P. Dunn (U.S. Representative, FL-2, Republican)

Follow

Following needs an Agora account. You will sign in first, then come back to this page.

From Congress.gov and official rosters. This record was last updated Aug 1, 2026. About our data

Summary

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

Summary from the Congressional Research Service. How we handle summaries

Where it stands

Assigned to a committee for review.

  1. Introduced
  2. In committee
  3. Up for a vote
  4. Passed one chamber
  5. Passed
  6. Enacted

Committee

House Committee on Energy and Commerce · U.S. House of Representatives

Your position on this bill

Choose the position closest to yours. You'll sign in or create an account to save it.

Sign in or create an account to give your position

Cosponsors

1

Cosponsors listed on Congress.gov, shown A to Z.

  • Democratic1

Shown in neutral colors by design; Agora is non-partisan.

Related bills

As identified by Congress.gov.

Full history

  1. Mar 5, 2025

    Introduced

    Introduced in House

    U.S. House of Representatives

  2. Mar 5, 2025

    Introduced

    Introduced in U.S. House

    U.S. House

  3. Mar 5, 2025

    Referred to committee

    Referred to the House Committee on Energy and Commerce.

    U.S. House of Representatives

Read the record